1063 patents
Page 5 of 54
Utility
Triazolopyridinyl compounds as kinase inhibitors
26 Sep 23
Guanglin Luo, Jie Chen, Carolyn Diane Dzierba, David B. Frennesson, Junqing Guo, Amy C. Hart, Xirui Hu, Michael C. Mertzman, Matthew Reiser Patton, Jianliang Shi, Steven H. Spergel, Brian Lee Venables, Yong-Jin Wu, Zili Xiao, Michael G. Yang
Filed: 18 Oct 21
Utility
Method of treating lung cancer
26 Sep 23
This disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
Marina Tschaika
Filed: 8 Jul 21
Utility
TL1A antibodies and methods of treatment
26 Sep 23
Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A.
Achal Mukundrao Pashine, Guodong Chen
Filed: 1 Mar 21
Utility
Biomarkers for Nanoparticle Compositions
21 Sep 23
The present application provides methods and compositions for treating cancer by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and a carrier protein (such as an albumin) based upon the status of one or more mTOR-activating aberration at one or more genes selected from the group consisting of TSC1, TSC2, RPS6, PTEN, TP53, RB1, ATRX, and FAT1.
Neil P. DESAI, Anita N. SCHMID, Shihe HOU, Andrew KWON
Filed: 19 Dec 22
Utility
Methods of Treating Tumor
21 Sep 23
The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the subject a monotherapy comprising an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody.
Prabhu Seshaiyer BHAGAVATHEESWARAN, Nicholas Allan John BOTWOOD, Han CHANG, William J. GEESE, Sabine MAIER, Giovanni SELVAGGI, Joseph Daniel SZUSTAKOWSKI
Filed: 17 Oct 22
Utility
AGONISTS OF ROR GAMMAt
21 Sep 23
The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
Lalgudi S. Harikrishnan, Brian E. Fink, Patrice Gill, Lan-Ying Qin, Muthoni G. Kamau, Tram N. Huynh, Ashok Vinayak Purandare, Honghe Wan, Daniel O’Malley
Filed: 8 May 20
Utility
Methods for Culturing Cells and Kits and Apparatus for Same
21 Sep 23
Provided herein are methods that relate, in some aspects, to the incubation or culturing, such as to induce stimulation of expansion (proliferation), activation, costimulation and/or survival, of a composition of cells, such as a population of lymphocytes.
Lothar Germeroth, Christian Stemberger, Patricia Graf, Keenan Bashour
Filed: 7 Oct 22
Utility
1H-BENZO[D]IMIDAZOLE Derivatives As TLR9 Inhibitors for the Treatment of Fibrosis
21 Sep 23
David S. Yoon, Alicia Regueiro-Ren, Michael Mandler, Shoshana L. Posy, Chunjian Liu
Filed: 18 Aug 21
Utility
Methods of Treating Tumor
21 Sep 23
The disclosure provides a method for treating a subject afflicted with a tumor, e.g., lung cancer, having a high tumor mutation burden (TMB) status comprising administering to the subject an immunotherapy, e.g., an anti-PD-1 antibody or antigen-binding portion thereof.
Prabhu Seshaiyer BHAGAVATHEESWARAN, Nicholas Allan John BOTWOOD, Han CHANG, Yali FU, William J. GEESE, George A. GREEN, Diane HEALEY, Sabine MAIER, Faith E. NATHAN, Abderrahim OUKESSOU, Giovanni SELVAGGI, Joseph Daniel SZUSTAKOWSKI
Filed: 7 Dec 22
Utility
Methods of Treating Autoimmune Disease Using a Domain Antibody Directed Against CD40L
21 Sep 23
Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, Pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided.
MAREK HONCZARENKO, VAISHALI SHAH, LIXIN LANG, URVI ARAS, DIANE SHEVELL, CHRISTINE KRATT, KAREN PRICE, SUZANNE SUCHARD
Filed: 21 Sep 22
Utility
Heteroaryl compounds useful as MK2 inhibitors
19 Sep 23
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Jian Guo, John Malona, Alexander L. Ruchelman, Sekhar S. Surapaneni
Filed: 17 Sep 21
Utility
Methods of selecting therapeutic molecules
19 Sep 23
The present disclosure provides methods of using a calcium oscillation assay and/or a sequence score calculation to identify a molecule that is safe for administration.
Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Niels Fisker Nielsen, Dong LI, Jeffrey M. Brown, Stephen E. Mercer, Marianne Lerbech Jensen
Filed: 4 Feb 16
Utility
Methods of antibody production that minimize disulfide bond reduction
19 Sep 23
The present disclosure discloses methods for purifying antibodies providing an air overlay or headspace to single-use storage bags containing the antibody during purification.
John C. Fann, Brian W. O'Mara, Laura R. Smith
Filed: 24 Apr 18
Utility
Histone Demethylase Inhibitors
14 Sep 23
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease.
Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
Filed: 24 Mar 23
Utility
Enhancing Anti-cancer Activity of Immunomodulatory FC
Fusion Proteins
14 Sep 23
The present disclosure provides a method for enhancing the anti-tumor efficacy of an Fc fusion protein which binds specifically to a target, e.g., a co-inhibitory or co-stimulatory receptor of ligand, on a T cell in a subject afflicted with a cancer or a disease caused by an infectious agent and alters the activity of the immunomodulatory target, thereby potentiating an endogenous immune response against cells of the cancer or the infectious agent, wherein the method comprises selecting, designing or modifying the Fc region of the Fc fusion protein so as to enhance the binding of said Fc region to an activating Fc receptor (FcR).
John J. ENGELHARDT, Alan J. KORMAN, Michael QUIGLEY, Mark J. SELBY, Changyu WANG
Filed: 27 Feb 23
Utility
Methods of Treating a Tumor Using an ANTI-PD-1 Antibody
7 Sep 23
This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity.
Robin EDWARDS, William J. GEESE, Danielle M. GREENAWALT
Filed: 30 Jan 23
Utility
METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONS
7 Sep 23
The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous(SC) for treating immune system diseases and tolerance induction.
Manisha P Desai, Charles E. Dahlheim, Sunita Borsadia, Vijay H. Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
Filed: 3 Nov 22
Utility
Combination Therapy with ANTI-IL-8 Antibodies and ANTI-PD-1 Antibodies for Treating Cancer
7 Sep 23
Provided herein are methods for the clinical treatment of tumors (e.g., advanced solid tumors) in patients having certain levels of serum IL-8 using an anti-IL-8 antibody in combination with an anti-PD-1 antibody.
Michael CARLETON, David FELTQUATE, Olivier DE HENAU, Timothy Patrick REILLY, Tian CHEN, Ye FENG, Shu-Pang Ben HUANG, Ming ZHOU, Ramachandran SURESH
Filed: 29 Dec 22
Utility
Supramolecular filamentous assemblies for protein purification
5 Sep 23
The present invention provide novel immunofiber compositions for protein or peptide purification and simple and cost-efficient methods and systems using these compositions.
Honggang Cui, Yi Li, Lye Lin Lock, XuanKuo Xu, Zhengjian Li
Filed: 17 Aug 18
Utility
Process for the Preparation of 6-(CYCLOPROPANEAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE
31 Aug 23
Ke Chen, Joerg Deerberg, Dong Lin, Michael Dummeldinger, Bahar Inankur, Sergei Kolotuchin, Jun Li, Amanda J. Rogers, Victor W. Rosso, Eric M. Simmons, Maxime C.D. Soumeillant, Daniel S. Treitler, Jianji Wang, Bin Zheng, Michael J. Smith, Neil A. Strotman, Steven Tymonko, Tamas Benkovics
Filed: 13 Apr 23